Theravance Biopharma (TBPH) Non-Current Deffered Revenue (2013 - 2023)

Theravance Biopharma (TBPH) has reported Non-Current Deffered Revenue for 11 consecutive years, with $175000.0 the latest figure, recorded in Q3 2023.

• In Q3 2023, Non-Current Deffered Revenue fell 12.06% year-over-year to $175000.0; the TTM figure through Sep 2023 stood at $175000.0 (down 12.06% YoY), while the FY2022 annual figure was $192000.0, down 38.06% from the prior year.
• Non-Current Deffered Revenue eased to $175000.0 in Q3 2023 per TBPH's latest filing, from $181000.0 in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $21.7 million in Q1 2019 and bottomed at $175000.0 in Q3 2023.
• Historically, Non-Current Deffered Revenue has averaged $3.7 million across 5 years, with a median of $329000.0 in 2021.
• Annual changes were most pronounced in 2019 — Non-Current Deffered Revenue surged 101.32% — and 2021, when it tumbled 96.02%.
• Theravance Biopharma's Non-Current Deffered Revenue stood at $6.8 million in 2019, then sank by 94.85% to $348000.0 in 2020, then declined by 10.92% to $310000.0 in 2021, then slumped by 38.06% to $192000.0 in 2022, then dropped by 8.85% to $175000.0 in 2023.
• Business Quant data shows TBPH's Non-Current Deffered Revenue at $175000.0 in Q3 2023, $181000.0 in Q2 2023, and $187000.0 in Q1 2023.